Analysts Offer Predictions for MIRM Q2 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.36) per share for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals’s revenue was up 61.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.54) earnings per share.

A number of other equities analysts have also recently commented on MIRM. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Raymond James reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Finally, JMP Securities increased their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research note on Friday, May 9th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $60.73.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $45.34 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm’s fifty day moving average price is $42.97 and its two-hundred day moving average price is $44.55. The firm has a market capitalization of $2.25 billion, a P/E ratio of -22.45 and a beta of 0.95. Mirum Pharmaceuticals has a 1 year low of $23.83 and a 1 year high of $54.23.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. CWM LLC raised its stake in Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after acquiring an additional 428 shares during the period. Jones Financial Companies Lllp increased its position in Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after acquiring an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Mirum Pharmaceuticals during the 4th quarter worth $35,000. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at $42,000.

Insiders Place Their Bets

In other news, COO Peter Radovich sold 7,879 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. The trade was a 29.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 92,764 shares of company stock valued at $4,109,161 in the last ninety days. Corporate insiders own 14.36% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.